De novo and secondary acute myeloid leukemia in patients over the age of 65: A review of fifty-six successive and unselected cases from a general hospital

Leukemia and Lymphoma

Volumn 35, Issue 3-4, 1999, Pages 289-296

  Bauduer, Frédéric ^a,d   Ducout, Louis ^b   Dastugue, Nicole ^c   Capdupuy, Claudie ^a   Renoux, Michel ^a  

^a CH Côte Basque ^*  (France)

^b Laboratory of Hematology   (France)

^c CHU PURPAN   (France)

^d Service des Maladies du Sang   (France)

Author keywords

Acute myelogenous leukemia; Elderly patients; Myelodysplastic syndromes; Myeloproliferative syndromes; Secondary

Indexed keywords

AMPHOTERICIN B; ANTIBIOTIC AGENT; ANTILEUKEMIC AGENT; BLEOMYCIN; BUSULFAN; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; FOLINIC ACID; HYDROXYUREA; IDARUBICIN; MITOXANTRONE; PIPOBROMAN; PREDNISOLONE; VINDESINE;

ACUTE GRANULOCYTIC LEUKEMIA; AGED; ARTICLE; CANCER CLASSIFICATION; CANCER MORTALITY; CANCER PALLIATIVE THERAPY; FEVER; GENERAL HOSPITAL; GERIATRIC PATIENT; HUMAN; LEUKOCYTOSIS; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; METASTASIS; MYELODYSPLASTIC SYNDROME; MYELOPROLIFERATIVE DISORDER; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; SURVIVAL TIME;

EID: 0032732822     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.3109/10428199909145732     Document Type: Article

References (37)

1. Rees, J.K.H., Gray, R.G., Swirsky, D., Hayhoe, F.G. (1986). Principal results of the Medical Research Council's 8th acute myeloid leukaemia trial. Lancet, ii, 1236-1241.
2. Bennett, J.M., Catovsky, D., Daniel, M.T., Flandrin, G., Galton, D.A.G., Gralnick, H.R., Sultan, C. (1985). Proposed criteria for the classification of acute myeloid leukemia. Ann Intern Med, 103, 620-624.
3. Groupe Français de Morphologie Hematologique. (1987). French registry of acute leukemia and myelodysplastic syndromes: age distribution and hemogram analysis of the 4496 cases recorded during 1982-1983 and classified according to FAB criteria. Cancer, 60, 1385-1394.
4. Copplestone, J.A., Prentice, A.G. (1988). Acute myeloblastic leukaemia in the elderly. Leuk Res, 12, 617-625.
5. DeLima, M., Ghaddar, H., Pierce, S., Estey, E. (1996). Treatment of newly-diagnosed acute myelogenous leukaemia in patients aged 80 years and above. Br J Haematol, 93, 89-95.
6. Baudard, M., Marie, J.P., Cadiou, M., Viguie, F., Zittoun, R. (1994). Acute myelogenous leukaemia in the elderly: retrospective study of 235 consecutive patients. Br J Haematol, 86, 82-91.
7. Toronto Leukemia Study Group. (1986). Results of chemotherapy for unselected patients with acute myeloblastic leukemia: effect of exclusions on the interpretation of results. Lancet, i, 786-788.
8. Wahlin, A., Hörnsten, P., Jonsson, H. (1991). Remission rate and survival in acute myeloid leukemia: impact of selection and chemotherapy. Eur J Haematol, 46, 240-247.
9. Löwenberg, B., Zittoun, R., Kerkhofs, H., Jehn, U., Abels, J., Debusscher, L., Cauchie, C.H., Peetermans, M., Solbu, P., Suciu, S., Stryckmans, P. (1989). On the value of intensive remission-induction chemotherapy in elderly patients of 65 + years with acute myeloid leukemia: a randomized phase III study of the European Organization for Research and Treatment of Cancer, Leukemia group. J Clin Oncol, 7, 1268-1274.
10. Orlandi, E., Lazzarino, M., Morra, E., Castagnola, C., Alessandrino, E.P., Bernasconi, P., Bonfichi, M., Bernasconi, C. (1990). Impact of advanced age on the management of acute nonlymphocytic leukemia: a study of 103 patients. Acta Haematol, 84, 144-148.
11. Wynne, H., Woodhouse, K.W. (1987). The disposition of cytotoxic drugs in the elderly. Bailliere's Clin Haematol, 1, 513-531.
12. Balducci, L., Parker, M., Sexton, W., Tantranond, P. (1989). Pharmacology of antineoplastic agents in the elderly patients. Semin Oncol, 16, 76-84.
13. Botnick, L.E., Hannon, E.C., Obbagy, J., Hellman, S. (1982). The variation of hematopoietic stem cell self renewal capacity as a function of age: further evidence for heterogeneity of the stem cell compartment. Blood, 60, 268-271.
14. Michels, S.D., Mc Kenna, R.W., Arthur, D.C. (1985). Therapy-related acute myeloid leukemia and myelodysplastic syndrome: a clinical and morphological study of 65 cases. Blood, 65, 1364-1370.
15. Kantarjian, H.M., Keating, M.J., Walters, R.J. (1986). Therapy-related leukemia and myelodysplastic syndrome: clinical, cytogenetic, and prognostic features. J Clin Oncol, 4, 1748-1755.
16. Hoyle, C.F., de Bastos, M., Wheatley, K. (1989). AML associated with previous cytotoxic therapy, MDS or myeloproliferative disorders: results from the MRC's 9th AML trial. Br J Haematol. 72, 45-53.
17. Johnson, P.R.E., Liu Yin, J.A. (1993) Acute myeloid leukaemia in the elderly: biology and treatment. Br J Haematol, 83, 1-6.
18. Griffin, J.D., Löwenberg, B. (1986). Clonogenic cells in acute myeloblastic leukemia. Blood, 68, 1185-1195.
19. Hassan, H.T., Rees, J.K.H. (1990). Relation between age and blast cell differentiation in acute myeloid leukemia patients. Oncology, 47, 439-442.
20. Leith, C.J., Kopecky, K.J., Godwin, J., McConnell, T., Slovak, M.L., Chen, I.M., Head, D.R., Appelbaum, F.R., Willman, C.L. (1997). Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study. Blood, 89, 3323-3329.
21. Bauduer, F., Ducout, L., Dastugue, N., Capdupuy, C., Renoux, M. (1998). Epidemiology of myelodysplastic syndromes in a French general hospital of the Basque Country. Leuk Res, 22, 205-208.
22. Thirman, M., Larson, R.A. (1996). Therapy-related myeloid leukemia. Hematol Oncol Clin North Am, 10, 293-300.
23. Bauduer, F., Delmer, A., Blanc, M.C., Delmas-Marsalet, B., Cadiou, M., Rio, B., Marie, J.P., Zittoun, R. (1993). Treatment of chronic myelogenous leukemia in blast crisis and in accelerated phase with high- or intermediate-dose cytosine urabinoside and amsacrine. Leuk Lymphoma, 10, 195-200.
24. Peterson, P., Murphy, S., Hand, H.J., Geller, S.A., Ellis, J.T. (1994). Occurrence of acute leukaemia in treated essential thrombocythaemia. Lab Invest, 70, 118a.
25. Najean, Y., Rain, J.D., for the French Polycythemia Study Group. (1997). Treatment of polycythemia vera: the use of hydroxyurea and pipobroman in 292 patients under the age of 65 years. Blood, 90, 3370-3377.
26. Sterkers, Y., Preudhomme, C., Laï, J.L., Demory, J.L., Caulier, M.T., Wattel, E., Bordessoule, D., Bauters, F., Fenaux, P. (1998). Acute myeloid leukemia and myelodysplastic syndromes following essential thrombocythemia treated with hydroxyurea: a high proportion of cases with 17p deletion. Blood, 91, 616-622.
27. Barosi, G., Ambrosetti, A., Centra, A. for the Italian cooperative study group on myelofibrosis with myeloid metaplasia.(1998). Splenectomy and risk of blast transformation in myelofibrosis with myeloid metaplasia. Blood, 91, 3630-3636.
28. Copplestone, J.A., Smith, A.G., Osmond, C. (1989). Treatment of acute myeloid leukemia in the elderly: a clinical dilemna. Hematol Oncol, 7, 53-59.
29. Hamblin, T. (1992). The treatment of acute myeloid leukemia preceded by the myelodysplastic syndrome. Leuk Res, 16, 101-108.
30. Sebban, C., Archimbaud, E., Coiffier, B. (1988). Treatment of acute myeloid leukemia in elderly patients. A retrospective study. Cancer, 61, 227-233.
31. Tilly, H., Castaigne, S., Bordessoule, D., Casassus, P., Le Prise, P.Y., Tertian, G., Desablens, B., Henry-Amar, M., Degos, L. (1990). Low-dose cytarabine versus intensive chemotherapy in the treatment of acute non lymphocytic leukemia in the elderly. J Clin Oncol, 8, 272-279.
32. Büchner, T., Hiddemann, W., Koenigsmann, M. (1991). Recombinant human granulocyte-macrophage colony-stimulating factor after chemotherapy in patients with acute myeloid leukemia at higher age or after relapse. Blood, 78, 1190-1197.
33. Rowe, J.M., Andersen, J., Mazza, J.J. (1993). Phase III randomized placebo-controlled study of granulocyte-macrophage colony stimulating factor (GM-CSF) in adults patients (55-70 years) with acute myelogenous leukemia (AML): a study of the Eastern Cooperative Oncology Group (ECOG). Blood, 82 (suppl 1), 329 a.
34. Stone, R.M., Berg, D.T., George, S.L., Dodge, R.K., Paciucci, P.A., Schulman, P., Lee, E.J., Moore, J.O., Powell, B.L., Schiffer, C.A. (1995). Granulocyte-macrophage colony stimulating factor after initial chemotherapy for elderly patients with primary acute myelogenous leukemia. N Engl J Med, 332, 1671-1677.
35. Dombret, H., Chastang, C., Fenaux, P., Reiffers, J., Bordessoule, D., Bouabdallah, R., Mandelli, F., Ferrant, A., Auzanneau, G., Tilly, H., Yver, A., Degos, L. (1995). A controlled study of recombinant human granulocyte colony-stimulating factor in elderly patients after treatment for acute myelogenous leukemia. N Engl J Med, 332, 1678-1683.
36. Ferrara, F., Mirto, S. (1996). Serum LDH value as a predictor of clinical outcome in acute myelogenous leukaemia of the elderly. Br J Haematol, 92, 627-631.
37. Johnson, P.R.E., Ryder, W.D., Liu Yin, J.A. (1995) Validation of a model to predict survival in elderly patients with acute myeloid leukaemia. Br J Haematol, 90, 954-956.